Anticipated Upcoming Milestones: FTD-GRN: Initiate dosing for Cohort 2 FTD-GRN patients in 1H 2024. Report full 6-month safety and biomarker data from Cohort 1 patients in 2H 2024. Report 12-month follow-up data from Cohort 1 patients in 1H 2025. Report initial safety and biomarker data from Cohort 2 patients in 1H 2025. FTD-C9orf72 and ALS. Obtain regulatory feedback on the pathway to treating FTD-C9orf72 and ALS patients with PBFT02 in 2H 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PASG:
- Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
- Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
- Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
- Passage Bio expects cash to fund operations into 4Q25
- Passage Bio reports Q3 EPS (49c), consensus (46c)
